Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05617794

Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness

Conditions: Myopia, Myopia Progression, Juvenile Myopia

Sex: All
Ages: 8 Years – 14 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 30
Sponsor: SightGlass Vision, Inc.

Location: Canada

Summary

The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.

Eligibility Criteria

Inclusion Criteria:Are 8-14 years of age;Are able to read (or be read to), understand and sign the assent document;Are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document;Are emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D inclusively;Are willing and able to follow instructions.Exclusion Criteria:Are participating in any concurrent interventional clinical or research study;Have a history of myopia control treatment in the past year;Have amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency;Have any known active ocular disease and/or infection;Have a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism;Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops;Have undergone strabismus surgery, refractive error surgery or intraocular surgery;Are a child of a member of the study team.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05617794). StuddyBuddy aggregates publicly available trial information.